Background: Activation of the immune-inflammatory response system (IRS) and the compensatory immune-regulatory system (CIRS) play a key role in SCZ and treatment resistant SCZ. There are only few data on immune and endogenous opioid system (EOS) interactions in SCZ and treatment resistant SCZ.
Introduction
The first comprehensive neuro-immune theory of schizophrenia (SCZ) was published by Smith and Maes in 1995 and suggested that activated monocytes and Tlymphocytes are key phenomena in the pathophysiology of SCZ (Smith and Maes 1995) . Now, it is widely accepted that SCZ is accompanied by activation of the immuneinflammatory response system (IRS) with activated M1 macrophages as indicated by increased levels of interleukin (IL)-6, IL-1β and tumor necrosis factor alpha (TNFα) levels, T-helper (Th)-1 cells and Th-17 cells (Al-Hakeim et al., 2019a; Almulla et al., 2019; Maes et al., 2019c; Noto et al., 2015; 2019; Roomruangwong et al., 2019; Rubesa et al., 2018) . SCZ is also accompanied by activation of the compensatory immune-regulatory system (CIRS) with increased activity of Th-2 immunocytes as indicated by increased levels of IL-4 and IL-13, and T-regulatory (Treg) cells with increased production of IL-10, and elevated levels of immune-regulatory compounds including acute phase proteins (e.g. haptoglobin) and soluble interleukin receptors such as sIL-2R, sIL-1RA, sTNFR1 and sTNFR2 Roomruangwong et al., 2019) . Importantly, IRS and CIRS products including IL-1β, TNF-α, IL-6, IFN-γ, IL-4, IL-13, eotaxin (CCL11) and neurotoxic tryptophan catabolites (TRYCATs) may all cause neuroprogression and, as a consequence, deficits in memory and executive functions and, therefore, SCZ symptoms (Al-Hakeim et al., 2019a; Kanchanatawan et al., 2018; 2019b; 2019c; 2019d; Sirivichayakul et al., 2019a; 2019b) .
Treatment resistant schizophrenia (TRS) is also accompanied by signs of IRS and CIRS including M1 (especially IL-6 trans-signaling and TNFα) and Treg (IL-10) cell activation as well as increased levels of soluble IL-2 receptor (sIL-2R), sIL-1R antagonist (sIL-1RA), and sTNFR2 (Al-Hakeim et al., 2019a; Maes et al., 2000; Noto et al., 2015; Roomruangwong et al., 2019) .
Endogenous opioids (EOs) are expressed in the peripheral and central nervous system where they modulate pain, reward, aversion, reinforcement, social bonding, and neurotransmitter signaling including that of glutamate and dopamine (Charles et al., 2020; Corder et al., 2018) . During IRS activation, immunocytes produce and release EOs (Plein and Rittner 2018) and express µ (MOR) and κ (KOR) opioid receptors (Li et al., 2009) . In humans and animal models, EOs negatively regulate immune responses (Hu et al., 1998; Sacerdote, 2006) including downregulation of cytokine and chemokine levels and associated receptors (Finley et al., 2008) and immune cell proliferation and activities (McLaughlin et al., 2015) . Aberrations in EO system (EOS) activity are observed in SCZ including changes in the levels of endorphins, and MOR and KOR expression (Schwarzer et al., 2009); (Ashok et al., 2019) . In post-mortem brain of SCZ patients, lowered MOR expression is observed in the striatum (Ashok et al., 2019) . Because MORs mediate hedonic and social reward processing, lowered MOR expression may explain social impairments and other negative symptoms of SCZ (Trezza et al., 2011) . β-Endorphin concentrations are increased in SCZ patients with negative symptoms and decreased in patients with positive symptoms as compared with controls (Urban-Kowalczyk et al., 2016) . Interestingly, clinical reports indicate that some SCZ patients are less sensitive to pain (Szűcs et al., 2016) , suggesting increased EOS activity. Endomorphin-2, another EOS peptide, has high selectivity and affinity for MOR and mediates stress responses, sensitivity to pain, arousal, vigilance, reward, neuroendocrine and neurocognitive functions (Fichna et al., 2007) , suggesting that this peptide may play a role in SCZ.
In major depression, significant associations were established between increased plasma KOR/MOR levels, on the one hand, and elevated plasma IL-6 and IL-10, on the other, indicating that immune -EOS interactions play a role in the pathophysiology of depression (Al-Hakeim et al., 2019b) . Furthermore, IL-6 regulates the KOR gene (Jenab and Morris 2000) and MOR expression (Börner et al., 2004) , while IL-10 increases βendorphin gene and protein expression (Wu et al., 2018) . Since KOR/MOR/β-endorphin have immune-regulatory effects and since these products are upregulated in major depression, it was hypothesized that their increased levels may contribute to CIRS functions in depression (Al-Hakeim et al., 2019b) . However, in SCZ and TRS no data are available on endomorphin 2 and possible associations between EOS compounds and IRS/CIRS functions.
Hence, this study was performed to examine serum levels of β-endorphin and endomorphin 2 as well as MOR and KOR in association with IL-6 and IL-10 in SCZ and TRS.
Participants and Methods

Participants
In the current study, two groups of SCZ patients participated, namely 60 non responders to treatment (NRTT) and 55 partial responders to treatment (PRTT) and 43 healthy volunteers. The participants were of both sexes and aged 18-65 years. NRTT and PRTT were recruited at the Psychiatry Unit at Al-Imam Al-Hussain Medical City in Karbala (418/2019) 
Measurements
Clinical evaluations
A senior psychiatrist specialized in SCZ diagnosed the patients according to DSM-IV-TR criteria using the Mini-International Neuropsychiatric Interview (MINI), in a validated Arabic translation (Iraqi dialect). The same psychiatrist employed a semistructured interview to assess socio-demographic and clinical data in all participants and the same day he also assessed the Clinical Global Impression (CGI) Improvement (CGI-I) and Severity (CGI-S) Scales (Guy, 2000) . The CGI-I was used to identify NRTT when they did not show any improvement on the CGI-I or showed poorer scores after treatment (minimally worse, much worse, very much worse). The diagnosis "responders to treatment" was made in case the CGI-I scores improved minimally, much or very much.
However, since no patients showed remission after treatment this group was named PRTT. Furthermore, we assessed the Scale for the Assessments of Negative Symptoms (SANS) to measure severity of negative symptoms (Andreasen, 1989) . We also computed z unitweighted composite scores to reflect severity of psychosis, hostility, excitation, mannerism, FTD (formal thought disorders) and PMR (psycho-motor retardation) (Kanchanatawan et al., 2018; 2019d; Sirivichayakul et al., 2019a) .
Toward this end, we assessed the Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham 1962) , the Hamilton Depression Rating Scale (Hamilton, 1960) and the Positive and Negative Syndrome Scale (PANNS) (Kay et al., 1987) . The same psychiatrist also completed the Brief Assessment of Cognition in SCZ (BACS) (Keefe et al., 2004) to assess episodic memory (using the List learning test); working memory (using the Digit Sequencing Task); verbal fluency (using the Controlled Word Association and Category instances tests); attention (using the symbol coding test); and executive functions (using the Tower of London). Tobacco use disorder (TUD) was examined according to DSM-IV-TR criteria. Body mass index (BMI) was calculated from the formula: body weight (kg) / squared length (m 2 ).
Assays
Five milliliters of venous blood samples were collected after an overnight fast between 8.00 and 9.00 a.m. After clotting, blood was centrifuged at 3000 rpm for 10 min, and serum was separated and transferred into two Eppendorf tubes which were stored at -80 °C until analysis. Serum levels of IL-10 (Elabscience ® , Inc. CA, USA), MOR, KOR, and endomorphin 2 (Mybiosource ® , Inc. CA, USA), and IL-6 and β-endorphin (Melsin Medical Co, Jilin, China) were assayed used commercial ELISA kits. All measured concentrations of β-endorphins (sensitivity=0.1pg/mL), MOR (sensitivity=7.18 pg/mL), KOR (sensitivity=1.0 ng/mL), endomorphin 2 (sensitivity=0.33 pg/mL), and IL-6 (sensitivity=0.1 pg/mL) were greater than their assay sensitivities. There was only one IL-10 measurement (namely 4.05 pg/mL in a normal volunteer) that was lower than the sensitivity of the assay (sensitivity=4.69 pg/mL). Therefore, we did not apply left-censoring of the data and employed the measured IL-10 concentration in our statistical analyses (Al-Hakeim et al., 2019a) . All intra-assay coefficients of variation were < 10.0%.
Serum CRP was measured using a kit supplied by Spinreact ® , Spain, using a test based on the latex agglutination principle.
Statistical analysis
We used analysis of variance to check the differences in scale variables between categories and Chi square test (χ2-test) to assess the associations between categorical variables. Associations among biomarkers, cognitive and clinical scores were computed employing Pearson's product-moment and Spearman's rank-order correlation coefficients.
Associations between diagnosis and biomarkers were examined using multivariate general linear model (GLM) analysis while controlling for confounding variables including age, sex, TUD, BMI, and education. Consequently, we performed tests for between-subject effects to delineate the associations between diagnosis and each of the biomarkers. The effect size was assessed using partial eta-squared values (η 2 ). We also computed the modelgenerated estimated marginal mean (SE) values and used protected pairwise comparisons among treatment means to assess differences between the diagnostic groups. Binary logistic regression analysis was employed to delineate the best predictors of SCZ versus controls and NRTT versus PRTT using the serum biomarkers levels as explanatory variables. Nagelkerke values, which were used as pseudo-R 2 values, were computed along with Odd's ratios with 95% confidence intervals. We used multiple regression analysis to assess the significant biomarkers, which predict the neurocognitive test results and symptom dimensions while permitting for probable effects of education, age, and sex. We used an automatic stepwise method with the inclusion of variables with a p-to-entry of 0.05 and p-to-remove of 0.06 while checking the R 2 change. All regression analyses were checked for collinearity using tolerance and variance inflation factor (VIF) values. Tests were 2-tailed and a p-value of 0.05 was used for statistical significance. All statistical analyses were performed using IBM SPSS windows version 25, 2017.
Results. Table 1 shows the sociodemographic data of the PRTT and NRTT and healthy controls. We included 142 SCZ patients who were treated with antipsychotic drugs during two trials with antipsychotic medications. During the first trial, patients were treated for 2 months and after this trial divided into those with a partial response (n=51) and those without a clinical response (n=84) (we lost seven patients through this first trial). The partial responders continued to take the similar medication for another two months while we missed again seven patients in the follow up producing a final PRTT study group of n=55. The non-responders to the initial antipsychotic drug were switched to another antipsychotic drug for another 2 months and during this follow-up period we missed again thirteen patients. Two months later, eleven patients had a partial response to treatment and were categorized as PRTT, whereas sixty patients did not show any improvement on the CGI-I and, therefore, were categorized as NRTT. Consequently, fifty-five PRTT and sixty NRTT participated in the current study.
Socio-demographic data
There were no significant differences in age, BMI, sex ratio, and TUD between NRTT and PRTT and normal controls. There were slightly more NRTT patients who were single as compared with the normal control group. SCZ patients were significantly more unemployed as compared with controls while years of education were slightly lower in NRTT. There were no differences in age at onset between both patients' subgroups. All six cognitive test scores were significantly different among the 3 study groups and the scores decreased from controls to PRTT to NRTT. The total SANS score was significantly different between the three study groups.
In Table 1 , both the CGI-I and CGI-S scores were significantly higher in NRTT than in PRTT. The CGI-I scores in PRTT were 2 (much improved) -3 (minimally improved) and in NRTT 4 (no change) -5 (minimally worse). Patients in the NRTT group were more often treated with clozapine, risperidone, and quetiapine than PRTT who were more often treated with haloperidol and olanzapine.
The following symptom domains were significantly different between the three study groups and increased from controls to PRTT to NRTT: excitement (F=320.71, df=2/152, p<0.001), FTD (F=414.15, df=2/152, p<0.001), hostility (F=498.12, df=2/152, p<0.001), mannerism (F=204.41, df=2/152, p<0.001), PMR (F=297.46, df=2/152, p<0.001) and psychosis (F=772.55, df=2/152, p<0.001
In the whole study group, there were significant correlations between IL-6 and βendorphin (ρ=0.173, p=0.03), endomorphin 2 (ρ=0.253, p=0.001), KOR (ρ=0.491, p<0.001), MOR (ρ=0.333, p<0.001) and a significant association between IL-10 and MOR (ρ=0.385, p<0.001). MOR is correlated with KOR (ρ=0.449, p<0.001) while endomorphin 2 was correlated with β-endorphin (ρ=0.254, p=0.001) and KOR (ρ=0.385, p<0.001).
Differences in biomarkers between the study groups Table 2 displays the outcomes of a multivariate GLM analysis comparing the differences in the biomarkers between the three study groups while adjusting for age, BMI, and sex. There were significant differences in biomarkers between the study groups with an effect size of 0.213, while the covariates had no significant effects. Tests for betweensubject effects and Table 3 , which shows the estimated marginal mean (SE) values, indicate that all six biomarkers (except β-endorphin) were significantly higher in SCZ patients as compared with controls. Furthermore, β-endorphin, MOR, KOR and IL-6 were significantly higher in NRTT than in PRTT and controls. Endomorphin 2 was significantly different between the three groups and increased from controls to PRTT to NRTT. IL-10 was higher in NRTT than in controls while PRTT patients occupied an intermediate position. We also performed a multivariate GLM analysis examining the associations between the 6 biomarkers measured here and the diagnosis of SCZ versus normal controls while controlling for age, sex and BMI. This analysis showed that endomorphin 2, KOR, MOR, IL-6 and IL-10, but not β-endorphin (p=0.865) were significantly higher is SCZ than in controls (with or without p correction for false discovery rate). Table 4 shows the results of two binary logistic regression analyses examining the best predictors of SCZ (versus controls) and NRTT (versus PRTT) using an automatic stepwise method with biomarkers as explanatory variables while allowing for the effects of age, sex and education. The first regression analysis showed that SCZ was best predicted by increased levels of endomorphin 2, KOR, and IL-10 (χ2=39.338, df=3, p<0.001, Nagelkerke=0.319) with an accuracy of 72.2%, sensitivity of 74.8% and specificity of 65.1%. The second regression shows that the combination of endomorphin 2, MOR, and IL-6 best predicted NRTT versus PRTT (χ2=34.47, df=3, p<0.001, Nagelkerke=0.346) with an accuracy of 72.2%, sensitivity of 80.0% and a specificity of 76.5%.
Effects of background variables
As shown above, age, sex, and BMI had no significant effects on serum biomarker levels. TUD also had no significant effect on the measured biomarker levels (F=0.19, df=6/146, p=0.979, partial η 2 =0.008). We also examined the effects of antipsychotic drug administration using multivariate GLM analysis and tests for between-subjects. We found no significant effects of use of clozapine (F=0.63, df=6/146, p=0.704, partial η 2 =0.025), haloperidol (F=0.88, df=6/146, p=0.513, Partial η 2 =0.035), risperidone (F=0.92, df=6/146, p=0.484, partial η 2 =0.036), and quetiapine (F=0.93, df=6/146, p=0.476, partial η 2 =0.037).
However, use of olanzapine had a significant effect on the measured biomarkers (F=2.89, df=6/146, p=0.011, partial η 2 =0.106), although after p-correction for multiple testing this effect was no longer significant (p=0.195). Table 5 shows different stepwise multiple regression analyses with the symptom domains as dependent variables and the six biomarkers as explanatory variables while allowing for the effects of education, age and sex. Regression #1 shows that 28.0% of the variance in the total SANS score was explained by the regression on endomorphin 2, MOR, and IL-6. Regressions #2, #3, #4 and #5 show that the same variables explained a considerable part of the variance in psychosis (28.3%, but additionally with education), hostility (26.9%), excitation (22.4%), and PMR (28.4%). Regression #6 shows that 23.7% of the variance in mannerism was explained by endomorphin 2, MOR, KOR, and IL-10.
Prediction of symptom domains by biomarkers
Regression #7 shows that 27.8% of the variance in FTD was explained by the combined effects of endomorphin 2, MOR, IL-6, IL-10, and education. Partial correlation coefficients (adjusted for age, sex, and education) showed that all symptom profiles were significantly associated with plasma KOR kevels (all r>0.314, p<0.001, n=153), but not with βendorphin. Table 6 shows the outcome of 6 multiple regression analyses with the cognitive test results as dependent variables and biomarkers as explanatory variables while allowing for the effects of age, sex and education. We found that (regression #1) 16.3% of the variance in List Learning scores was explained by the regression on IL-6 and MOR (all inversely associated). Up to 21.4% of the variance in Digit Sequencing Task scores (regression #2) was explained by the combined effects of MOR, IL-6, endomorphin 2 (inversely) and education (positively). Part of the variance (20.2%) in Category Instances test scores (regression #3) was explained by MOR, endomorphin 2 (negatively) and education (positively). We found that 28.3% of the variance in the COWA test scores (regression #4) was explained by the cumulative effects of MOR, IL-6, endomorphin 2, and age (negatively) while 22.9% of the variance in symbol coding scores (#5) was negatively associated with KOR, IL-10, and endomorphin 2. Up to 29.3% of the variance in Tower of London test scores (regression #6) was explained by the combined effects of MOR, IL-6, endomorphin 2, sex (all inversely) and education (positively). Partial correlation coefficients (adjusted for age, sex, and education) showed that all cognitive tests results were significantly associated with plasma KOR (all r>0.206, p<0.01, n=152), but not with β-endorphin.
Prediction of cognitive impairments by biomarkers
Discussion
The first major finding of this study is that serum levels of KOR, MOR, endomorphin 2, IL-6 and IL-10 are significantly increased in SCZ as compared with controls. This is a first report on increased endomorphin 2 levels in SCZ. Volk et al. found that increased MOR mRNA and protein levels in SCZ are largely independent of illness severity, suggesting that increased MOR expression is part of the disease process rather than a consequence of illness chronicity (Volk et al., 2011) . In Han Chinese, a MOR polymorphism may confer risk for SCZ (Ding et al., 2013) while an A118G polymorphism of the MOR gene was associated with SCZ (Šerý et al., 2010) . One study reported lowered MOR availability in the brain of SCZ patients who died as a result of suicide, which would be consistent with increased levels of EOS peptides occupying those receptors (Scarr et al., 2012) . Our negative findings on β-endorphin levels in SCZ are not in agreement with those of a previous report (Ding et al., 2013) . Animal models of SCZ are accompanied by moderate alterations in EOS peptides (Ashok et al., 2019; Schwarzer et al., 2009; Volk et al., 2011; Szűcs et al., 2016; ) . Our findings on increased IL-6 and IL-10 levels in SCZ are in agreement with previous reports that SCZ is accompanied by enhanced IRS and CIRS functions (Roomruangwong et al., 2019) . This is also a first report that a non-response to treatment is characterized by increased MOR, endomorphin 2 and β-endorphin levels, indicating that the EOS participates in the pathophysiology of treatment resistance. Our findings that IL-6 is increased in NRTT as compared with PRTT is in accordance with previous reports that IL-6 and macrophage M1 activation are associated with TRS (Maes et al., 2000; Roomruangwong et al., 2019) . In the current study we found that serum IL-10 was significantly higher in NRTT than in controls, whereas PRTT occupied an intermediate position. Previous reports showed that TRS is accompanied by increased IL-10 levels (Maes et al., 2002) .
The second major finding of this study is that IL-6 levels are strongly associated with all four EOS biomarkers whilst IL-10 is associated with MOR concentrations only. in those conditions, inflammation is associated with increased MOR sensitivity in the periphery and in the brainstem (Hipólito et al., 2015) . Moreover, the combination of IL-6 with endomorphin 2 and MOR yielded a highly significant discrimination of NRTT from PRTT indicating that upregulation of the immune -EOS axis is associated with the pathophysiology of a non-response to treatment.
During activation of the IRS, immune cells produce a) opioid peptides, (Przewlocki et al., 1992; Panerai and Sacerdote, 1997) with increased EO concentrations in blood and inflammatory sites (Menzebach et al., 2003) ; and b) KOR and MOR (Bidlack 2000) , which are subsequently released in the circulation through shedding. Some T-cell subsets release cytokines and EOS peptides/receptors that can promote, suppress, or resolve pain (Basso et al., 2018 , Laumet et al., 2019 . Moreover, also endomorphin 2 may be produced by immunocytes in inflamed subcutaneous tissues, whereas this peptide is almost absent in non-inflamed tissue (Mousa et al., 2002) . In addition, MOR is expressed in macrophages and neutrophils, indicating that endomorphins produced during inflammation can stimulate MORs on the surface of these cells (Ninković and Roy 2013). As such, the positive intercorrelations detected in our study between increased IL-6 levels and EOS biomarkers, including endomorphin 2, suggest that the enhanced IRS/CIRS responses in SCZ patients and especially in NRTT are accompanied by increased production of EOS biomarkers. This may be important to brain functions as some EOS peptides including endomorphin 2 may cross the blood-brain barrier (BBB) following intraperitoneal administration (Chesnokova et al., 2013) . Ting et al. (1997) reported that increased MOR/KOR binding on the BBB precedes BBB disruption (Ting et al., 1997) . Moreover, recent research shows that SCZ and especially deficit SCZ is accompanied by a breakdown of the tight junction and vascular barriers of the BBB (Maes et al., 2019b) .
There is now evidence that the EOS exerts immune-regulatory activities through multiple feedback loops (Liang et al., 2016; Al-Hakeim et al., 2019b) . For example, EOS peptides/receptors modulate adaptive immune functions including attenuating Th functions and neutrophil chemotaxis (Grimm et al., 1998; Martin et al., 2010) , increasing T cell apoptosis (Martin et al., 2010) and levels of immune-regulatory cytokines including IL-10 (Li et al., 2009) . Increased MOR, KOR and β-endorphin levels display negative immuneregulatory properties as reviewed in (Al-Hakeim et al., 2019b) . Therefore, the latter authors concluded that in, major depression, increased dynorphin/KOR and β-endorphin/MOR signaling may contribute to CIRS functions (Al-Hakeim et al., 2019b) . In addition, endomorphin 2 may regulate neutrophil, macrophage and microglia functions even at ultra-low concentrations (Azuma and Ohura, 2003) . Yang et al. (2012) reported that activated dendritic cells induce their expression and secretion of endomorphins and that the latter, in turn, may suppress T lymphocyte proliferation through stimulation of MOR (Yang et al., 2012) . Endomorphin 2 not only regulates the production of pro-inflammatory cytokines, but also inhibits macrophage chemotaxis and the production of reactive oxygen species (ROS) by macrophages and neutrophils (Azuma et al., 2002; Azuma and Ohura, 2003) .
Importantly, in other inflammatory disorders, endomorphins exert anti-inflammatory actions (Jessop 2006; Straub et al., 2008) for example by inhibiting IL-8, but not IL-6 (Straub et al., 2008) . Moreover, endomorphin 2 is advocated as an agent to treat chronic inflammatory disease (Jessop 2006) . As such, all 4 EOS biomarkers measured here are produced by activated immunocytes and may, consequently, exert CIRS activities thereby regulating the immune response in SCZ patients and NRTT.
The third major finding of this study is that MOR, KOR and endomorphin 2 were associated with PHEMN (psychosis, hostility, excitation, mannerism, negative) symptoms, psychomotor retardation and formal thought disorders as well as neurocognitive deficits in memory, attention and executive functions. The detrimental effects of IL-6 and, especially, IL-6 trans-signaling on brain functions including neurocognitive functions are well established (Maes et al., 2014; Maes et al., 2019c; Roomruangwong et al., 2019) . Although the EOS may exert CIRS (see above discussion) and neuroprotective effects (Yang et al., 2012) , this system may have detrimental effects as well. For example, endomorphins may activate immune pathways, which may result in more detrimental effects, including increased IL-1β signaling, macrophage adhesion, expression of adhesion molecules on macrophages, and neutrophil chemotaxis (Azuma et al., 2002; Azuma and Ohura, 2003) .
Moreover, KOR agonists may exhibit psychotomimic properties while opioid antagonists may ameliorate SCZ symptoms (Clark and Abi-Dargham, 2019) . KOR activation and administration of KOR agonists including salvinorin A may induce hallucinations, anxiety, depression, negative-like symptoms (lack of motivation and social withdrawal), psychomotor retardation, dysphoria and neurocognitive impairments including in attention, working memory and task performance, which are quite similar to the effects of acute ketamine administration (Land et al., 2008; Nemeth et al., 2010; Shekhar, 2019) . These effects were explained by attenuated glutamate and dopamine release in the prefrontal cortex, which play a key role in neuropsychological functioning (Yoshikawa et al., 2009; Escobar et al., 2017) . Therefore, increased KOR expression as observed in our study may play a role in the pathophysiology of SCZ.
Moreover, endomorphin 2 may stimulate postsynaptic MORs causing postsynaptic hyperpolarization of excitatory interneurons (Heinke et al., 2011; Chen et al., 2015) .
Endomorphin 2 may additionally induce excitation, a bell-shaped dose-response curve for locomotor enhancement and aversive effects, and place aversion (Gelmana et al., 2010) .
As such, increased endomorphin 2 levels could, combined with increased KOR, contribute to the pathophysiology of a non-response to treatment. Finley, M.J., Chen, X., Bardi, G., Davey, P., Geller, E. B., Zhang, L., et al., 2008. Bi- directional heterologous desensitization between the major HIV-1 co-receptor CXCR4 and the κ-opioid receptor. J Neuroimmunol. 197(2): 114-123. Maes, M., Anderson, G., Kubera, M., Berk, M.J., 2014. Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? Expert Opin Ther Targets. 18(5) : 495-512. Maes, M., Kanchanatawan, B., Sirivichayakul, S., Carvalho, A.F., 2019a Yoshikawa, S., Hareyama, N., Ikeda, K., Kurokawa, T., Nakajima, M., Nakao, K., Mochizuki, H., Ichinose, H., 2009 . Effects of TRK-820, a selective kappa opioid receptor agonist, on rat schizophrenia models. Eur J Pharmacol. 606(1-3): 102-108. 
Conclusions
